- Advertisement -
[ad_1]
Firm stories leap in earnings amid robust gross sales of most cancers, lung and immunology therapies per week after pulling plug on Merseyside funding
AstraZeneca has reported a soar in annual earnings boosted by robust gross sales of its most cancers, lung and immunology therapies, per week after it determined to not go forward with a deliberate £450m funding in Merseyside, prompting a collection of recriminations with the federal government.
- Advertisement -
Britain’s greatest drugmaker, which can also be the biggest listed firm, stated revenues rose by 21% to $54.1bn (£43bn) in 2024. Pre-tax revenue jumped by 38% to $8.7bn final yr on a continuing foreign money foundation.
Continue studying…
[ad_2]
- Advertisement -
